Fluorouracil
Fluorouracil (5-FU) is an antimetabolite chemotherapy drug, a fluorinated analog of the pyrimidine base uracil, used in the treatment of a wide range of solid tumors.
Fluorouracil (5-FU) is an antimetabolite chemotherapy drug, a fluorinated analog of the pyrimidine base uracil, used in the treatment of a wide range of solid tumors. It has been a backbone of cytotoxic chemotherapy for decades and is central to the management of colorectal cancer, gastric cancer, pancreatic ductal adenocarcinoma, head and neck cancers including oral squamous cell carcinoma, and nasopharyngeal carcinoma. It is given intravenously for systemic disease and applied topically for certain skin lesions, and its oral prodrug capecitabine offers an alternative route of administration.
After cellular uptake, 5-FU is converted to active nucleotide metabolites. Its principal cytotoxic action is inhibition of thymidylate synthase, which depletes the thymidine nucleotides required for DNA synthesis and repair; incorporation of fluorinated metabolites into RNA and DNA contributes further damage. The resulting replication stress and DNA damage engage TP53-dependent responses and intrinsic apoptosis, with mitochondrial depolarization and caspase-3 activation, and cell-cycle arrest through downregulation of proliferation regulators such as MYC and CDK4. In practice 5-FU is rarely used alone: it is combined with leucovorin, which stabilizes its inhibitory complex with thymidylate synthase, and paired with oxaliplatin in FOLFOX regimens, with irinotecan for colorectal and pancreatic disease, and with cisplatin in head and neck protocols, as well as in neoadjuvant and adjuvant settings. Its clinical usefulness is constrained by short plasma half-life, limited bioavailability, dose-limiting systemic toxicity, and acquired resistance, which can arise through survival signaling such as Phosphatidylinositol 3-kinase (PI3K)/Protein kinase B (PKB), NF-κB, and MAPK/ERK/JNK pathways, altered apoptotic balance involving Bcl-2, and suppression of ferroptosis. These limitations motivate continued work on nanoparticle and polymer-based delivery systems, including chitosan and cyclodextrin carriers designed for pH-responsive release, and on combination strategies with natural products and targeted agents intended to resensitize resistant tumors.
Where the papers sit
35 papers from the last 6 months study fluorouracil directly · updated from PubMed 11 Nov 2026
Study type 0 clinical trials · 2 observational · 3 human data · 30 preclinical
Themes 5 themes · 2 new directions
-
Targeted Anticancer Drug Delivery
Stimuli-responsive carriers are moving 5-FU delivery toward tumor-triggered release rather than free-drug exposure. Redox-, pH-, thermal-, magnetic- and supramolecular systems recur across hydrogels, metal-organic frameworks, nanoclusters and implantable matrices. The intended gains are localized uptake, reduced toxicity and synergistic chemo-imaging or hyperthermia, with some designs also carrying 6-mercaptopurine. Evidence remains mainly computational and preclinical, so release control and tumor selectivity still require in vivo and clinical validation.
10 papers · 28.6%
-
Apoptosis-Based Chemotherapy Sensitization
5-FU efficacy is being strengthened by forcing oxidative, mitochondrial and caspase-dependent apoptosis in resistant cancer cells. Recurrent readouts include ROS, BAX/BCL2 balance, CASP3 activation, cell-cycle arrest and reduced angiogenesis, especially in colorectal models. Malformin A1, vorinostat, engineered probiotics and pH-responsive nanocarriers represent distinct combination strategies, while cuproptosis appears as an additional mechanism in some studies. The evidence is preclinical and supports sensitization, but comparative durability and safety remain open.
10 papers · 28.6%
-
Gastrointestinal Chemotherapy
Gastrointestinal chemotherapy is moving toward localized delivery, bioimaging guidance and molecularly selected response. Enteric prodrug particles, implantable 5-FU@ZIF-8 fibers and gastroprotective carriers aim to improve exposure while limiting systemic or mucosal toxicity. PIK3C3 has divergent effects on 5-FU sensitivity in KRAS-wild-type and KRAS-mutant tumors, making genotype relevant to treatment design. Clinical experience with hepatic infusion and regorafenib shows feasibility in advanced disease, but efficacy evidence remains uneven.
6 papers · 17.1%
-
Gastric Cancer Chemoresistance
5-FU and cisplatin response in gastric cancer is being linked to DNA repair, ferroptosis and pathway-level biomarkers. PARG-driven PARylation stabilization of RAD51AP1 supports homologous-recombination repair and chemoresistance, while PTPRE suppresses ferroptosis through Src/FAK/TRIB3. CDO1 and co-expression signatures extend this work toward prognostic and treatment-response stratification through PI3K/AKT-THBS1 signaling. Patient-derived models and xenografts remain important for testing whether these mechanisms yield actionable sensitizers.
5 papers · 14.3%
-
Anticancer Chemotherapy Development
Chemotherapy development is moving toward regimen selection informed by tumor genomics and disease setting. In pancreatic cancer, genomic profiles and molecular subtypes are being tested as modifiers of adjuvant benefit, with KRAS status central to interpretation. In advanced disease, liposomal irinotecan plus 5-FU/LV is evaluated as a second-line option alongside clinical and economic outcomes. Natural-product and nanohybrid studies broaden the preclinical search for agents, but their relevance to pancreatic care remains unestablished.
4 papers · 11.4%
Fluorouracil is repurposed from an anticancer drug as an antibacterial adjuvant against methicillin-resistant Staphylococcus aureus
The methicillin-resistant Staphylococcus aureus study treated 5-fluorouracil as a pyrimidine antimetabolite in antibacterial combinations rather than as cancer chemotherapy. It found that guanosine depleted bacterial thymidine, potentiated 5-fluorouracil and 5-fluorouridine, and, when combined with oxacillin, enhanced killing of both planktonic and biofilm-associated MRSA. This extends fluorouracil into treatment of drug-resistant bacterial infection, a role outside the anticancer delivery, sensitization, and chemotherapy categories used by the other papers 42268235Jun.
Fluorouracil is repurposed as a local antifibrotic after glaucoma surgery
The glaucoma-surgery wound-healing study treats 5-fluorouracil as an antimetabolite for localized, time-controlled suppression of postoperative fibroblast overgrowth rather than as a cancer chemotherapeutic. Its engineered nanostructured film is designed to release defined doses at the surgical site to reduce the fibroblastic response that can obstruct drainage channels, extending fluorouracil’s role to postoperative ocular wound control 42297313Jun.
Papers
The 35 papers from the last 6 months that study fluorouracil directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
Targeted Anticancer Drug Delivery (10)
- Zirconium metal-organic framework-based composite drug delivery system for precise drug release and synergistic modulation of the tumor microenvironment in liver cancer therapy. Acta biomaterialia · 3 Sept 2026 PMID 42692231
- Tumor-Responsive Delivery of 5-Fluorouracil from a Redox-Triggered Supramolecular Gelator. Bioconjugate chemistry · 19 Aug 2026 PMID 42615515
- Magneto-Fluorescent Mn-Doped CD@ZIF-8@Kappa Carrageenan Biohydrogel-A Dual Model Therapeutic and Diagnostic Agent for Targeted Drug Delivery and Cancer Therapy. ACS applied bio materials · 17 Aug 2026 PMID 42606071
- Multifunctional Magnetothermo-Responsive Smart Hydrogel for On-Demand Controlled Drug Release in Cancer Therapy. ACS applied materials & interfaces · 9 Aug 2026 PMID 42571655
- Towards a combined skin cancer treatment: the macrocyclic effect of pillar[5]arene containing 6-mercaptopurine fragments, integrated with an exfoliating serine protease and 5-fluorouracil. Bioorganic chemistry · 9 Jul 2026 PMID 42424925
- Multiscale modeling unveils molecular mechanisms of deep eutectic solvent-anticancer drug interactions for rational formulation design. International journal of pharmaceutics · 17 Jun 2026 PMID 42309199
- Functionalized smart surfaces to control the wound healing after glaucoma's surgery. International journal of pharmaceutics · 15 Jun 2026 PMID 42297313
- DFT study on interaction of anticancer drugs with Pd2L4 metallo-organic cage carrier. Journal of molecular graphics & modelling · 3 Jun 2026 PMID 42235324
- Siligraphene as targeted carrier for 5-FU anticancer drug delivery with smart release: A first-principles study. Computational biology and chemistry · 2 Jun 2026 PMID 42229149
- Comparative DFT investigation of glutathione-mediated drug release from Au 13 , A g 13 , and P t 13 nanoclusters: implications for metal-selective anticancer drug delivery. Journal of molecular modeling · 21 May 2026 PMID 42165898
Apoptosis-Based Chemotherapy Sensitization (10)
- Synergistic antitumor effects of 5-fluorouracil and vorinostat in preclinical models of pheochromocytomas and paragangliomas. Endocrine · 10 Oct 2026 PMID 42859296
- Engineered probiotics for tumor-targeted combination chemoimmunotherapy. Science translational medicine · 16 Sept 2026 PMID 42748218
- Smart thermo/pH-responsive Janus nanogel for synergistic chemo-magnetic hyperthermia therapy inducing caspase-mediated apoptosis in the BALB/c 4T1 breast cancer model. International journal of pharmaceutics · 3 Sept 2026 PMID 42692379
- Malformin A1 Enhances 5-Fluorouracil-induced Apoptosis, Cell Cycle Arrest, and Anti-angiogenesis in Colorectal Cancer Cells. Anticancer research · 31 Aug 2026 PMID 42674697
- 5-Fluorouracil loaded copper-aluminum layered double hydroxides inhibit colorectal cancer cells by inducing oxidative stress, mitochondrial membrane depolarization, apoptosis, and cell cycle arrest. Bioorganic chemistry · 15 Jul 2026 PMID 42456411
- Chitosan/β-cyclodextrin nanocarriers enhance 5-fluorouracil efficacy against colorectal cancer via pH-responsive release and apoptosis modulation. Scientific reports · 7 Jul 2026 PMID 42414363
- Integrative multi-omics and machine learning reveal PLAUR as a Pan-Cancer prognostic biomarker and potential therapeutic target. Bioorganic chemistry · 2 Jul 2026 PMID 42391812
- Heteronemin suppresses chemoresistant oral squamous cell carcinoma cells through ROS-mediated apoptosis and cuproptosis-associated mitochondrial stress. Apoptosis : an international journal on programmed cell death · 18 Jun 2026 PMID 42315805
- The β-lactam adjuvant guanosine potentiates anti-folate antibiotics and pyrimidine synthesis inhibitors by depleting thymidine in methicillin-resistant Staphylococcus aureus. Antimicrobial agents and chemotherapy · 10 Jun 2026 PMID 42268235
- Inhibitory effects of mycosubtilin on proliferation of colon cancer SW480 cells. PloS one · 20 May 2026 PMID 42160403
Gastrointestinal Chemotherapy (6)
- Resolution of Severe Jaundice Following Hepatic Artery Infusion of Bevacizumab and 5-Fluorouracil With Oral Regorafenib in Metastatic Colorectal Cancer:A Case Report. The American journal of case reports · 4 Nov 2026 PMID 42981239
- Divergent Roles of PIK3C3 in KRAS-Wild-Type and KRAS-Mutant Advanced Colorectal Cancer: Implications for 5-Fluorouracil Sensitivity and Prognosis. Cancer medicine · 30 Oct 2026 PMID 42958604
- NIR-Activated Enteric Prodrug Microparticles for Bioimaging-Guided Chemotherapy of Colorectal Cancer. ACS applied materials & interfaces · 9 Aug 2026 PMID 42571659
- Safety and Feasibility of Biweekly Divided-dose of DCF as Neoadjuvant Chemotherapy for Esophageal Squamous Cell Carcinoma. Anticancer research · 29 Jul 2026 PMID 42527061
- Implantable 5-FU@ZIF-8 core-shell nanofiber fabricated via emulsion electrospinning: a pH-responsive strategy for localized chemotherapy. International journal of pharmaceutics · 17 Jul 2026 PMID 42468654
- Hierarchically Structured CaCO3-Gelatin Carriers for Oral Gastro-Protective Delivery of Broccoli Seed-Derived Isothiocyanates in Combined Chemotherapy of Colorectal Cancer. ACS applied materials & interfaces · 19 Jun 2026 PMID 42319756
Gastric Cancer Chemoresistance (5)
- Integrated in silico and in vitro analysis identifies a co-expression pattern associated with cisplatin/5-FU treatment response and metastatic features in gastric cancer. Molecular biology reports · 16 Oct 2026 PMID 42886301
- CDO1 as a prognostic biomarker and therapeutic target in gastric cancer: Mechanistic insights into the PI3K/AKT-THBS1 axis and epigenetic reactivation by decitabine. Clinical and translational medicine · 31 Aug 2026 PMID 42670236
- Downregulation of SLC44A4 in nasopharyngeal carcinoma is associated with malignant progression, B-cell/TLS-related immune features, and sensitivity to DNA-damaging agents. PloS one · 26 Jun 2026 PMID 42361082
- PARG Governs a PARylation-Ubiquitination Toggle that Stabilizes RAD51AP1 to Drive Homologous Recombination-Mediated Chemoresistance. Cancer research · 18 Jun 2026 PMID 42314057
- PTPRE promotes gastric cancer cell resistance to 5-fluorouracil by inhibiting ferroptosis via the Src/FAK/TRIB3 axis. PloS one · 18 Jun 2026 PMID 42313735
Anticancer Chemotherapy Development (4)
- Impact of Tumor Genomic Profile on Adjuvant Chemotherapy Efficacy in Resected Pancreatic Adenocarcinoma: Results From the PRODIGE-24/CCTG PA6 Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 3 Aug 2026 PMID 42546248
- Economic evaluation of the second-line regimen of liposome irinotecan (II) combined with 5-FU/LV versus placebo combined with 5-FU/LV for locally advanced or metastatic pancreatic ductal adenocarcinoma in China. PloS one · 22 Jun 2026 PMID 42329888
- Nitrogen-containing dihydro-β-agarofuran derivatives and macrocyclic spermidine alkaloids with anti-tumor activity from the stems of Tripterygium wilfordii. Fitoterapia · 15 Jun 2026 PMID 42297080
- Unveiling the Potential Therapeutic Efficacy of Gold Ceria Nanohybrid as an Anticancer Agent: A Special Insight to Molecular Docking Study. ACS applied bio materials · 4 Jun 2026 PMID 42240071
By study type
Observational studies and case reports (2)
- Resolution of Severe Jaundice Following Hepatic Artery Infusion of Bevacizumab and 5-Fluorouracil With Oral Regorafenib in Metastatic Colorectal Cancer:A Case Report. The American journal of case reports · 4 Nov 2026 PMID 42981239
- Safety and Feasibility of Biweekly Divided-dose of DCF as Neoadjuvant Chemotherapy for Esophageal Squamous Cell Carcinoma. Anticancer research · 29 Jul 2026 PMID 42527061
Human data, design not indexed (3)
- Impact of Tumor Genomic Profile on Adjuvant Chemotherapy Efficacy in Resected Pancreatic Adenocarcinoma: Results From the PRODIGE-24/CCTG PA6 Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 3 Aug 2026 PMID 42546248
- Economic evaluation of the second-line regimen of liposome irinotecan (II) combined with 5-FU/LV versus placebo combined with 5-FU/LV for locally advanced or metastatic pancreatic ductal adenocarcinoma in China. PloS one · 22 Jun 2026 PMID 42329888
- Comparative DFT investigation of glutathione-mediated drug release from Au 13 , A g 13 , and P t 13 nanoclusters: implications for metal-selective anticancer drug delivery. Journal of molecular modeling · 21 May 2026 PMID 42165898
Preclinical: animal, cell and lab studies (30)
- Divergent Roles of PIK3C3 in KRAS-Wild-Type and KRAS-Mutant Advanced Colorectal Cancer: Implications for 5-Fluorouracil Sensitivity and Prognosis. Cancer medicine · 30 Oct 2026 PMID 42958604
- Integrated in silico and in vitro analysis identifies a co-expression pattern associated with cisplatin/5-FU treatment response and metastatic features in gastric cancer. Molecular biology reports · 16 Oct 2026 PMID 42886301
- Synergistic antitumor effects of 5-fluorouracil and vorinostat in preclinical models of pheochromocytomas and paragangliomas. Endocrine · 10 Oct 2026 PMID 42859296
- Engineered probiotics for tumor-targeted combination chemoimmunotherapy. Science translational medicine · 16 Sept 2026 PMID 42748218
- Smart thermo/pH-responsive Janus nanogel for synergistic chemo-magnetic hyperthermia therapy inducing caspase-mediated apoptosis in the BALB/c 4T1 breast cancer model. International journal of pharmaceutics · 3 Sept 2026 PMID 42692379
- Zirconium metal-organic framework-based composite drug delivery system for precise drug release and synergistic modulation of the tumor microenvironment in liver cancer therapy. Acta biomaterialia · 3 Sept 2026 PMID 42692231
- Malformin A1 Enhances 5-Fluorouracil-induced Apoptosis, Cell Cycle Arrest, and Anti-angiogenesis in Colorectal Cancer Cells. Anticancer research · 31 Aug 2026 PMID 42674697
- CDO1 as a prognostic biomarker and therapeutic target in gastric cancer: Mechanistic insights into the PI3K/AKT-THBS1 axis and epigenetic reactivation by decitabine. Clinical and translational medicine · 31 Aug 2026 PMID 42670236
- Tumor-Responsive Delivery of 5-Fluorouracil from a Redox-Triggered Supramolecular Gelator. Bioconjugate chemistry · 19 Aug 2026 PMID 42615515
- Magneto-Fluorescent Mn-Doped CD@ZIF-8@Kappa Carrageenan Biohydrogel-A Dual Model Therapeutic and Diagnostic Agent for Targeted Drug Delivery and Cancer Therapy. ACS applied bio materials · 17 Aug 2026 PMID 42606071
- NIR-Activated Enteric Prodrug Microparticles for Bioimaging-Guided Chemotherapy of Colorectal Cancer. ACS applied materials & interfaces · 9 Aug 2026 PMID 42571659
- Multifunctional Magnetothermo-Responsive Smart Hydrogel for On-Demand Controlled Drug Release in Cancer Therapy. ACS applied materials & interfaces · 9 Aug 2026 PMID 42571655
- Implantable 5-FU@ZIF-8 core-shell nanofiber fabricated via emulsion electrospinning: a pH-responsive strategy for localized chemotherapy. International journal of pharmaceutics · 17 Jul 2026 PMID 42468654
- 5-Fluorouracil loaded copper-aluminum layered double hydroxides inhibit colorectal cancer cells by inducing oxidative stress, mitochondrial membrane depolarization, apoptosis, and cell cycle arrest. Bioorganic chemistry · 15 Jul 2026 PMID 42456411
- Towards a combined skin cancer treatment: the macrocyclic effect of pillar[5]arene containing 6-mercaptopurine fragments, integrated with an exfoliating serine protease and 5-fluorouracil. Bioorganic chemistry · 9 Jul 2026 PMID 42424925
- Chitosan/β-cyclodextrin nanocarriers enhance 5-fluorouracil efficacy against colorectal cancer via pH-responsive release and apoptosis modulation. Scientific reports · 7 Jul 2026 PMID 42414363
- Integrative multi-omics and machine learning reveal PLAUR as a Pan-Cancer prognostic biomarker and potential therapeutic target. Bioorganic chemistry · 2 Jul 2026 PMID 42391812
- Downregulation of SLC44A4 in nasopharyngeal carcinoma is associated with malignant progression, B-cell/TLS-related immune features, and sensitivity to DNA-damaging agents. PloS one · 26 Jun 2026 PMID 42361082
- Hierarchically Structured CaCO3-Gelatin Carriers for Oral Gastro-Protective Delivery of Broccoli Seed-Derived Isothiocyanates in Combined Chemotherapy of Colorectal Cancer. ACS applied materials & interfaces · 19 Jun 2026 PMID 42319756
- Heteronemin suppresses chemoresistant oral squamous cell carcinoma cells through ROS-mediated apoptosis and cuproptosis-associated mitochondrial stress. Apoptosis : an international journal on programmed cell death · 18 Jun 2026 PMID 42315805
- PARG Governs a PARylation-Ubiquitination Toggle that Stabilizes RAD51AP1 to Drive Homologous Recombination-Mediated Chemoresistance. Cancer research · 18 Jun 2026 PMID 42314057
- PTPRE promotes gastric cancer cell resistance to 5-fluorouracil by inhibiting ferroptosis via the Src/FAK/TRIB3 axis. PloS one · 18 Jun 2026 PMID 42313735
- Multiscale modeling unveils molecular mechanisms of deep eutectic solvent-anticancer drug interactions for rational formulation design. International journal of pharmaceutics · 17 Jun 2026 PMID 42309199
- Functionalized smart surfaces to control the wound healing after glaucoma's surgery. International journal of pharmaceutics · 15 Jun 2026 PMID 42297313
- Nitrogen-containing dihydro-β-agarofuran derivatives and macrocyclic spermidine alkaloids with anti-tumor activity from the stems of Tripterygium wilfordii. Fitoterapia · 15 Jun 2026 PMID 42297080
- The β-lactam adjuvant guanosine potentiates anti-folate antibiotics and pyrimidine synthesis inhibitors by depleting thymidine in methicillin-resistant Staphylococcus aureus. Antimicrobial agents and chemotherapy · 10 Jun 2026 PMID 42268235
- Unveiling the Potential Therapeutic Efficacy of Gold Ceria Nanohybrid as an Anticancer Agent: A Special Insight to Molecular Docking Study. ACS applied bio materials · 4 Jun 2026 PMID 42240071
- DFT study on interaction of anticancer drugs with Pd2L4 metallo-organic cage carrier. Journal of molecular graphics & modelling · 3 Jun 2026 PMID 42235324
- Siligraphene as targeted carrier for 5-FU anticancer drug delivery with smart release: A first-principles study. Computational biology and chemistry · 2 Jun 2026 PMID 42229149
- Inhibitory effects of mycosubtilin on proliferation of colon cancer SW480 cells. PloS one · 20 May 2026 PMID 42160403
Written from 35 PubMed abstracts, each one listed by PMID above. Published: 2026-06-17. Last written: 2026-09-18 by GPT. Reviewed by a human editor on 2026-07-23. Drafted by language models from published abstracts; not medical advice.